Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 6, pp 1095–1107

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

  • Xavier García del Muro
  • Enrique Gallardo
  • Iciar García Carbonero
  • Nuria Laínez
  • María José Méndez
  • Pablo Maroto
  • María Ochoa de Olza
  • Javier Puente
  • Gaspar Reynes
  • José Rubio
  • Carmen Santander
  • Cristina Suárez
  • Sergio Vázquez Estévez
  • Daniel Castellano
Review Article

DOI: 10.1007/s00280-014-2413-0

Cite this article as:
García del Muro, X., Gallardo, E., García Carbonero, I. et al. Cancer Chemother Pharmacol (2014) 73: 1095. doi:10.1007/s00280-014-2413-0

Abstract

Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques and active surveillance. But 50 % of patients may develop disease recurrence attributable to subclinical metastases. In these cases, and considering the low benefits of chemotherapy, new targeted therapies such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have been developed as first- and second-line treatment. Both sunitinib and pazopanib are TKIs that constitute the first-line treatment option in patients with metastatic RCC. As second-line treatment, sequential therapy with a second TKI or a mTOR inhibitor is recommended. This review has collected together a series of recommendations issued by the Spanish Oncology Genitourinary Group with the aim of facilitating the treatment of these patients. Each recommendation is accompanied by the level of evidence and grade of recommendation on the basis of the available data.

Keywords

Diagnosis Nephrectomy Renal cell carcinoma Tyrosine kinase inhibitor 

Abbreviations

ASCO

American Society of Clinical Oncology

CT

Computed tomography

DFS

Disease-free survival

ECOG

Eastern Cooperative Oncology Group

EORTC

European Organization for Research and Treatment of Cancer

ESMO

European Society of Medical Oncology

HIFU

High-intensity focused ultrasound

HR

Hazard ratio

IL

Interleukin

mTOR

Mammalian target of rapamycin

OS

Overall survival

PFS

Progression-free survival

PS

Performance status

RCC

Renal cell carcinoma

SOGUG

Spanish Oncology Genitourinary Group

SWOG

Southwest Oncology Group

TKI

Tyrosine kinase inhibitor

ULN

Upper limit of normal

VEGF

Vascular endothelial growth factor

VEGFR

Vascular endothelia growth factor receptor

WHO

World Health Organization

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Xavier García del Muro
    • 1
  • Enrique Gallardo
    • 2
  • Iciar García Carbonero
    • 3
  • Nuria Laínez
    • 4
  • María José Méndez
    • 5
  • Pablo Maroto
    • 6
  • María Ochoa de Olza
    • 7
  • Javier Puente
    • 8
  • Gaspar Reynes
    • 9
  • José Rubio
    • 10
  • Carmen Santander
    • 11
  • Cristina Suárez
    • 12
  • Sergio Vázquez Estévez
    • 13
  • Daniel Castellano
    • 14
  1. 1.Genitourinary and Sarcoma Unit, Department of Medical OncologyInstitut Català d’Oncologia L’HospitaletL’Hospitalet, BarcelonaSpain
  2. 2.Hospital Parc TaulíSabadellSpain
  3. 3.Hospital Virgen de la SaludToledoSpain
  4. 4.Hospital de NavarraPamplonaSpain
  5. 5.Hospital Universitario Reina SofíaCórdobaSpain
  6. 6.Hospital de la Santa Creu i Sant PauBarcelonaSpain
  7. 7.Institut Català d’Oncologia L’HospitaletL’HospitalatetSpain
  8. 8.Hospital Universitario San CarlosMadridSpain
  9. 9.Hospital Universitario La FeValenciaSpain
  10. 10.Instituto Valenciano de OncologíaValenciaSpain
  11. 11.Hospital Universitario Miguel ServetZaragozaSpain
  12. 12.Hospital Vall d’HebronBarcelonaSpain
  13. 13.Hospital Lucus AgustiLugoSpain
  14. 14.Hospital Universitario 12 de OctubreMadridSpain

Personalised recommendations